Table 1 Overview of selected SNPs

From: Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?

SNP

Genotypes (n) or reason of exclusion

Gene

Location

Function

Alleles

Alternative name(s)

Inclusion reference

Callrate

HW χ 2

rs6265

G/G (78); A/G (43); A/A (5)

BDNF

11p13

Missense

G/A

Val66Met

Licinio et al.44

1.00

0.262

rs11030101

A/A (36); T/A (63); T/T (27)

BDNF

11p13

UTR-5

A/T

 

Licinio et al.44

1.00

0.109

rs11030102

C/C (76); G/C (43); G/G (7)

BDNF

11p13

NearGene-5

C/G

 

Licinio et al.44

1.00

0.004

rs11030103

Design failure

BDNF

11p13

NearGene-5

G/A

 

Licinio et al.44

/

/

rs12273539

No variation

BDNF

11p13

Intronic

T/C

 

Licinio et al.44

1.00

/

rs28722151

*Suspected*

BDNF

11p13

UTR-5

C/G

 

Licinio et al.44

/

/

rs56820186

Design failure

BDNF

11p13

UTR-3

G/T

 

Licinio et al.44

/

/

rs57083135

Too little variation

BDNF

11p13

NearGene-5

C/T

 

Licinio et al.44

1.00

0.031

rs4633

C/C (31); C/T (63); T/T (32)

COMT

22q11.21

Synonymous

C/T

 

Diatschenko et al.51

1.00

0.009

rs4680

G/G (31); G/A (63); A/A (32)

COMT

22q11.21

Missense

G/A

Val158Met

Diatschenko et al.51

1.00

0.009

rs4818

C/C (41); C/G (64); G/G (21)

COMT

22q11.21

Synonymous

C/G

 

Diatschenko et al.51

1.00

0.362

rs6267

No variation

COMT

22q11.21

Missense

G/T

Ala72Ser

Diatschenko et al.51

1.00

/

rs6269

A/A (39); A/G (65); G/G (22)

COMT

22q11.21

NearGene-5

A/G

 

Diatschenko et al.51

1.00

0.479

rs324650

A/A (36); T/A (68); T/T (22)

CHRM2

7q31-q35

Intronic

A/T

 

Wang et al.45

1.00

0.762

rs1824024

T/T (56); G/T (50); G/G (20)

CHRM2

7q31-q35

Intronic

G/T

 

Wang et al.45

1.00

1.649

rs2061174

T/T (58); T/C (51); C/C (17)

CHRM2

7q31-q35

Intronic

C/T

 

Wang et al.45

1.00

0.717

rs6276

A/A (63); G/A (54); G/G (9)

DRD2

11q23

UTR-3

A/G

A1385G

Kraschewski et al.46

1.00

0.188

rs6277

T/T (38); C/T (63); C/C (25)

DRD2

11q23

Synonymous

C/T

C957T

Kraschewski et al.46

1.00

0.002

rs1799732

Design failure

DRD2

11q23

NearGene-5

−/C

−141C del

Kraschewski et al.46

/

/

rs747302

Genotyping failure

DRD4

11p15.5

NearGene-5

C/G

C616G

Ben Zion et al.43

0.06

/

rs936461

G/G (58); G/A (53); A/A (15)

DRD4

11p15.5

NearGene-5

A/G

A809G

Ben Zion et al.43

1.00

0.048

rs1800955

Too little variation

DRD4

11p15.5

NearGene-5

C/T

C521T

Ben Zion et al.43

0.93

5.165

rs1799836

Multivariable SNP

MAO-B

Xp11.23

Intronic

A/G

B-SNP 13

Balciuniene et al.47

/

/

rs495491

T/T (65); T/C (48); C/C (13)

OPRM1

6q24-q25

Intronic

C/T

 

Zhang et al.48

1.00

0.938

rs609148

C/C (75); C/T (44); T/T (7)

OPRM1

6q24-q25

Intronic

C/T

 

Zhang et al.48

1.00

0.068

rs648893

T/T (75); C/T (44); C/C (7)

OPRM1

6q24-q25

Intronic

C/T

 

Zhang et al.48

1.00

0.068

rs1799971

Too little variation

OPRM1

6q24-q25

Missense

A/G

Asn40Asp 118 A/G

Zhang et al.48

1.00

0.004

rs3823010

A/A (83); A/G (37); G/G (6)

OPRM1

6q24-q25

Intronic

A/G

 

Zhang et al.48

1.00

0.484

rs563649

Too little variation

OPRM1

6q24-q25

UTR-5

A/G

 

Shabalina et al.49

1.00

0.038

rs6347

A/A (68); A/G (49); G/G (9)

SLC6A3

5p15.3

Synonymous

A/G

Ex2+159 C>T

Azzato et al.50

1.00

0.006

rs6350

Too little variation

SLC6A3

5p15.3

Synonymous

C/T

−3714G>T

Azzato et al.50

1.00

0.607

rs6413429

Too little variation

SLC6A3

5p15.3

NearGene-5

G/T

Ex9–55A>G

Azzato et al.50

1.00

0.853

  1. Abbreviations: BDNF, brain-derived neurotrophic factor; CHRM2, cholinergic receptor muscarinic 2; COMT, catechol-O-methyltransferase; DRD2, dopamine receptor D2; DRD4, dopamine receptor D4; ESM, experience sampling methodology; OPRM1, μ1 opioid receptor; SLC6A3, dopamine transporter; SNP, single nucleotide length polymorphism; UTR, untranslated repeat. Note: call rates and X2 values of Hardy–Weinberg (HWχ2) equilibrium (both calculated on n=131; including five participants without ESM data) are indicated. SNPs with a callrate <0.90 (genotyping failure); no or too little variation (two or more genotypes with less than 30 subjects); or a X2 value above 10.83 (marked with *, corresponding with a P-value <0.001) were excluded from analyses.